The problem of "missing heritability" in genome-wide analyses of complex diseases is thought to be linkage genome-wide to estimate the probability that individual results were due to chance. We identified a 23 total of 12 putative susceptibility regions with per-family genome-wide probability < 0.05. These regions 24 were located on 10 chromosomes; 10 of the 22 families showed linkage at these locations; two or more 25 families showed linkage to 6 regions on 5 chromosomes (4q, 5q, 6p, 14q, 18p, and 18q). These results
linkage genome-wide to estimate the probability that individual results were due to chance. We identified a 23 total of 12 putative susceptibility regions with per-family genome-wide probability < 0.05. These regions 24 were located on 10 chromosomes; 10 of the 22 families showed linkage at these locations; two or more 25 families showed linkage to 6 regions on 5 chromosomes (4q, 5q, 6p, 14q, 18p, and 18q). These results 26 indicate that there is considerable heterogeneity among families in genomic regions and thus variants 27 predisposing to breast cancer. Moreover, they suggest that uncommon high-or medium-risk genetic 28 variants remain to be found, and that family designs can be an efficient way to identify them.
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Introduction. 30
The genetic dynamics of complex traits have concerned population scientists for more than a century, but the quantity 31 of data streaming from genomic studies in recent decades has drawn new focus to the prospect of identifying genes 32 underlying complex phenotypes. Especially important targets for genetic characterization are human disease 33 phenotypes that commonly plague us and frequently kill us, such as cancer. 34
Long before genome-wide data were available for complex trait analysis, family studies were the workhorses used to 35 study the genetic basis of cancer because case clusters were originally observed in families. Examination of familial 36 clusters of neoplastic disease led to the identification of the tumor suppressor role of TP53 [1] in Li-Fraumeni 37 syndrome, retinoblastoma, and the role of the FANC gene complex in Fanconi anemia (FA) . Family studies of breast 38 cancer also provided the first plausible evidence that a few genes of at least moderate effect might account for excess 39 risk and observed case aggregation in families. This result was established for BRCA1 and BRCA2 mutations in familial 40 breast and ovarian cancers [2] [3], and as a result the two genes were dubbed "most important" for breast cancer 41 predisposition in high risk families [4] . 42
Although breast cancer is not the most common of FA's neoplastic effects, it has been demonstrated fairly recently 43 that the products of the FANC gene complex function in congress with BRCA1 and BRCA2 in DNA repair pathways and 44 provisionally explains their concordant effects on breast cancer predisposition in some families [5] . Mutations in PTEN 45 and STK11 may also exhibit relatively high penetrance effects [6-9] while other genes, such as ATM, CHK2, and PALB1, 46 also account for excess breast cancer risk in some families with somewhat lower penetrance [10, 11] ; however, 47 families segregating these other mutations are rarer, and thus account for less of the total genetic risk estimated for 48 large and heterogeneous case series. In fact, no other genes as commonly mutated, or of such high penetrance as 49 BRCA1 and BRCA2, have been identified yet through family studies of breast cancer. Therefore, it has generally been 50
concluded from numerous studies of familial cancer risk (breast and other) in multiple populations, that: 1) the same 51 genes do not account for cancer incidence in all families with elevated risks of the same cancer; 2) the same genes are 52
Heterogeneity of familial breast cancer risk 4 not necessarily implicated in familial clusters and sporadic cases (without a family history), even in the same 53 population; and 3) familial cancers are relatively rare, and thus do not account for more than approximately 25% of all 54 cases in a population, or 20% of incident breast cancers [12] . For these reasons, much doubt has been expressed over 55 the last decade that family studies had much future utility for resolving complex genotypes for diseases like breast 56 cancer [13] . Instead, as genome-wide data rapidly became available, and with it an acute need for "high-throughput" 57 analyses, the focus of research quickly shifted to simpler association study designs to measure genetic differences 58 between phenotypic classes, such as cases and controls. 59
The genome-wide association study (GWAS) approach focuses on genotype-phenotype co-variation, usually for a 60 densely distributed set of SNPs over the genome. Positive associations occur where genotype differences correspond 61 to phenotype differences outside of what is expected under a null hypothesis, and their locations mark points in or 62 near genetic variants that cause disease or contribute to its risk. Numerous GWAS have been done in search of genes 63 that condition risk of breast cancer, and a list of genes and variants with modest effects on cancer risk has certainly 64 developed as a result [14] [15]. However, the small fraction of breast cancers attributable to these relatively common 65 but low-penetrance alleles suggests that a larger set of genetic factors, more of them reaching moderate effect, but 66 occurring with low frequency in a population, might account for such common cancer phenotypes. This "heritability 67 gap" has been considered a problem of statistical lack of power to resolve a potentially large number of genetic 68 variants, some of them low in frequency (rare), and of only moderate or low risk effect for common but deadly disease 69
phenotypes. 70
For complex diseases in general, GWAS have generated many significant associations between particular SNPs and 71 disease phenotypes, but again, these are often inconsistent across studies, populations, designs, and samples. After 72 more than a decade of modeling and measuring complex genotype-phenotype associations by GWAS, it remains 73 difficult to value the contributed effects of particular genes to a disease phenotype by this method, and today it is 74 widely appreciated that the approach has a critical shortcoming. For many individual studies the methodology is 75 Although it is now considerably easier and less expensive to collect genetic data for GWAS, it has remained elusive by 83 association testing to capture enough genetic variants, or of sufficient effect, to account for what is manifestly familial 84 and estimated as heritable. In this study we address the notion of "missing heritability" and compromised analytic 85 power for detecting genetic factors contributive to breast cancer. To do this, we have fashioned a "high-definition" 86 approach to linkage analysis using deep pedigree data, albeit sparsely genotyped, and for pairs related over a range of 87 relationships. The approach is not designed primarily to address the matter of heritability; more importantly, it is 88 designed to advance the train of evidence leading to the identification of genetic variants that are potentially rare-89 i.e., found at low population frequency-of moderate effect on risk, and likely larger in number than the class of single 90 used to establish diagnosed breast cancer cases clustered in large multigenerational families. We then compared 100 observed and expected breast cancer incidence in case families and recruited study subjects from "high risk" families, 101
i.e., those with excess incidence having a probability of less than 0.01 of occurring by chance [19] . However, we 102 excluded cases and families previously studied and known to be segregating BRCA1 or BRCA2 mutations as their 103 primary genetic risk factors for breast cancer. 104
Female members of high risk families who were diagnosed with breast cancer and alive at the start of the study were 105 invited to join, as were unaffected women drawn from the same large families. Study participants were home visited, 106 at which time individual and family health histories were documented and blood samples collected (by venous 107 puncture) as the source of DNA for genome-wide SNP analyses. 108
The genotyped study sample consisted of 154 women diagnosed with breast cancer, and 94 unaffected relatives. 109
"Families" were defined after recruitment as the largest set of genotyped subjects, including a minimum of 3 cases, all 110 descended from a common ancestor. By this method all participants (n=248) are members of 22 large families with 111 evident excess risk of breast cancer. Cases (n=154) collectively form 1,011 affected relative (AA) pairs for linkage 112 analysis; genotypes of unaffected subjects (94) were used to estimate allele frequencies and identity by descent 113 probabilities. The families included in this study are pictured schematically in Figure 1 . 114
The University of Utah Health Sciences Institutional Review Board and the University of Louisville Biomedical 115
Institutional Review Board approved the study protocol; all recruited subjects provided their written consent to be 116 included in this study. 117
118
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Heterogeneity of familial breast cancer risk 7 Genotyping was performed with Illumina 370 Duo and 610 Quad arrays at deCODE Genetics, Reykjavik, Iceland. SNPs 120 with low quality scores (GenCall[20] quality score < 0.15), and those with inconsistent allele frequencies between the 121 two arrays (any absolute difference in minor allele frequency > 0.05), were eliminated. All alleles were called on the 122 forward strand, and checked for consistency between arrays. After approximately 15% of the SNPs were eliminated by 123 these quality control criteria, a total of 285,630 genotypes per subject were retained. Mendelian consistency checks 124
were not performed because of the very small number of families with informative data. 125 126
Evaluation of genetic vs. genealogical relatedness 127
We examined the degree to which relatedness assessed by genome-wide genetic similarity corresponded to 128 relatedness as reported in the UPDB genealogical data for pairs of relatives. For this study, we used genotypes on 429 129 individuals, including the 248 subjects in the linkage study, as well as 181 women from families with fewer than 3 130 genotyped breast cancer cases. A total of 91,806 pairs were evaluated, using coefficient of relatedness to characterize 131 the genealogical data, and the genetic relatedness matrix computed by GCTA[21] to characterize relatedness from SNP 132 data. To facilitate comparison, relatedness from each measure was grouped by rounding -log2(relatedness) to 133 correspond to degree of relationship. 134
135
Identity by Descent (IBD) estimation for linkage analysis 136
Pairs formed from the sample set were used to generate Identity by Descent (IBD) matrices for linkage analysis. IBD 137 was computed using PEDIBD software developed by Li and colleagues [22] . Their method employs a Viterbi algorithm 138
[23] to find the most likely path of descent of an ancestral allele through a deep, but sparsely genotyped pedigree 139 structure, via hidden Markov models of inheritance and recombination. The method efficiently parses the high-density 140 genotype data of the Illumina arrays, permitting estimation of IBD matrices for 1,011 affected relative pairs at up to 141 285,630 loci in approximately 24 hours of CPU time on current equipment (substantially less for thinned data sets). as it appropriately adjusts for between-pair covariance when multiple relative pairs are drawn from the same pedigree 151 structure. Because the families studied vary considerably in size, and some have only a few affected members, the 152 distributional properties (and hence the asymptotic p-values) of the test statistic were uncertain. Therefore, we used 153 simulation to compute p-values and family-wise error rates. The approach is described below. 154
155
Simulation of Identity by Descent in the Absence of Linkage, but the Presence of Linkage Disequilibrium 156
We performed 100 full-genome simulations of identity by descent using all 285,630 autosomal markers and all 22 157 families for three reasons: 1) to allow accurate estimation of error rates for IBD estimates across all family structures 158 and all autosomes; 2) to give a reference against which different thinning strategies could be evaluated for their 159 effects on both IBD accuracy and the distribution of the linkage test statistic; and 3) to provide distributions of the test 160 statistic under the null hypothesis. 161 162
Estimation of error rates
It is well known that linkage analysis based on high-density SNP arrays is subject to potentially severe bias away from 164 the null because of linkage disequilibrium (LD). LD between nearby markers will cause overestimation of the 165 probability that two related individuals share marker alleles that are identical by descent (IBD) [26, 27] . Although in 166 principle, simultaneous modeling of LD among founders and IBD among descendants would be the most powerful 167 approach to using all the genotype data at our disposal [28] , the computational burden of such modeling in complex 168 multigenerational families is not readily surmountable at present. For simulation analyses, we imputed an LD structure descending from founders by adapting the HapMap3, Phase 2 178 observed LD structure for 234 independent haplotypes estimated from 117 CEU subjects [29] . The HapMap sample 179 series is appropriate as a reference set for this study because it too is a Utah family series [30] . HAPGEN2 software [31] 180 was used to generate 4000 random haplotypes with the desired LD characteristics for all 285,630 autosomal loci. For 181 each pedigree founder, two random haplotypes were chosen, from the 4000 randomly generated, by sampling with 182 replacement. Alleles for each SNP marker were randomly generated in proportion to each marker's allele frequencies. 183
Haplotypes were descended through the study pedigrees, resetting random segregation indicators according toHapMap's estimated recombination fractions. Recombination between markers was estimated by cubic spline 185 interpolation using R [32] . 186
Pedigree information and simulated marker data were input to PEDIBD to obtain a full matrix of IBD estimates for all 187 affected pairs. IBD estimates generated by PEDIBD were compared to the simulated "true" IBD states (0,
Distribution of test statistics under the null 191
The IBD estimates generated by PEDIBD were input to IBDREG to calculate linkage statistics. 
Results. 206
Heterogeneity of familial breast cancer risk 11 An initial check for correspondence between coefficients of relatedness estimated from pedigree information and 207 from SNP genotypes was made for all possible pairs of study subjects (see Methods). This information is plotted in 208
Figure 2 for pairs of related individuals. The most distantly related pairs in the genealogical data were 13 th degree 209 relatives, so pairs unrelated by genealogy and pairs estimated to be genetically more distant than 13 th degree were 210 plotted as though they were 14 th degree relatives on either scale. There was generally very good agreement between 211 genealogical and genetic distance up to about the 6 th degree, and a gradual loss of precision past that point in this 212
population. 213
It is common that some members of large Utah families overlap in family membership in descending generations, and 214 Table 1 gives counts of these individuals. Note that most subjects are members of only one family, and the majority of 215 those who overlap in family membership do so as pedigree members, rather than genotyped study subjects. This is 216
shown in Table 1 . where counts are given for the number of individuals with membership in >1 of the 22 families, by 217 disease status. Counts of individuals and affected pairs by family are given in Table 2 . 218
Simulations were done to depict the inflationary effect of LD on IBD and false positive linkage scores (see Methods). 219
These results are shown in Figure 3 and Table 3 . In order to control for this effect, and reduce false positive linkage 220 signal, SNPs were thinned to various thresholds of correlation between them. At the threshold R 2 ≤ 0.4, IBD over-221 estimation due to LD was controlled fairly well, but positive linkage peaks still occurred. At R 2 < 0.2, spurious linkage 222 peaks disappeared. The results given in Figure 4 and Table 4 are based on the inter-marker threshold R 2 < 0.2 for the 223 thinned set of 19,609 SNPs. 224 Table 4 gives linkage results for 1,011 affected relative pairs generated from a total of 154 genotyped breast cancer 225 cases. The analysis identified 19 distinct peaks with asymptotic unadjusted within-family p < 0.001. More realistic 226 estimates of the probability of these results under the null hypothesis are derived from the 100 per-family genome-227 wide simulations, and presented in Table 4 10-fold increase in asymptotic p-value. The large peak on chromosome 6 for family 1 includes multiple genes that have 236 been associated with breast cancer risk and/or tumorigenesis, including members of the HLA complex, NOTCH4, and 237 TNF, among others. Also noteworthy is that the chromosome 13 peak for family 10 includes BRCA2, while no family 238 exhibited linkage to the TP53 or BRCA1 regions on chromosome 17. 
Discussion. 242
It is low-frequency variants that are difficult to find in convincing association with a disease phenotype from genome-243 wide association tests [13] . However, if we are to resolve this low frequency, moderate risk class of variants, then 244 population-wide sampling from whole undifferentiated, or minimally structured populations, is perhaps not the most 245 strategic sampling approach to use. Variants of this class occur de novo, are replicated and transmitted to 246 descendants. For this reason, they will reach their highest frequencies within family lineages [36] , the larger the better, 247 while remaining at low frequency (rare) in any usual population sample, whether n = 100s or 100,000s. The moderate 248 risk nature of this class of variants is likely due to the fact that their risk effects depend on participation in larger gene 249 networks to account for increased cancer risk in particular families. In this sense, variants of smaller effect can alter 250 disease risk in the context of gene networks that regulate the functional pathways involved in the onset and/or 251 progression of the disease. 252
Heterogeneity of familial breast cancer risk 13 The family study approach does not rest on anticipating "a new breast cancer genotype", nor a "comprehensive 253 genotype" to account for breast cancer risk in this population and by the usual purview of linkage analysis. Instead, 254
we tried to capture evidence of low frequency variants at the population level, but enriched at the level of very large 255 high-risk families. Our approach yielded 17 genomic regions possibly linked (per-family per-genome Monte Carlo p < 256 0.1) to breast cancer for the 22 families studied, but with considerable variation among families: 15 of the 22 families 257 (68%) showed possible linkage to at least 1 region by the criteria used here; 1 family showed possible linkage to 4 258 regions; 1 family to 3 regions; 5 families to 2 regions; and 8 families showed linkage to 1 region. It is noteworthy that 259 linkage to the BRCA2 region on chromosome 13 was observed in only one family (10), while no family exhibited 260 linkage to the BRCA1 region on chromosome 17. 261
The availability of high-density marker sets, efficient algorithms for estimating IBD in large families, and substantial 262 computational resources permitted simulation of 100 null genome-wide results for each family. The simulation results 263 then allowed us to compare Monte Carlo p-values with asymptotic p-values based on large sample theory. In Table 4 it 264 is shown that the asymptotic estimates are frequently smaller than the Monte Carlo p-values by an order of 265 magnitude or more. The genome-wide results for each family represent an appropriate basis for comparison to other 266 published results based on linkage studies of one or a few families. Adjusting linkage estimates for all 22 families 267 simultaneously, we find no linkage scores, or peaks, that could not have occurred by chance: the observed Z-score of 268 6.21 for family 1 on 6p21-22 was exceeded in 90% of null simulations-for at least one family at some location over 269 the genome. However, in the simulated data, anomalously high Z-scores were much more commonly observed in 270 small families-and never in family 1-so the adjustment across families is in some part size dependent, and 271 therefore, less than perfect. For this reason, it might be more appropriate to consider the simulated probability of 272 observing the result in 22 families just like family 1, which would be approximately 1-(1-0.0018)^22 = 0.039. Moreover, 273 the existence of a possible linkage peak for family 5 in precisely the same location as family 1 on 6p21-22 strengthens 274 the case for a susceptibility locus in this region. In addition, the other regions suggestive of linkage without known breast cancer associated variants, might provide 283 useful new clues about the location of genetic variants that increase the risk of breast cancer in members of these 284 families, and serve as evidence of residual heterogeneity in genomic regions responsible for familial cancer 285
susceptibility. 286
Although this linkage analysis was meant to identify regions of the genome that include putative genetic contributors 287 to disease, there is still considerable distance between regions identified by linkage, and discovery of whether or what 288 variants within them contribute to breast cancer risk ("true positives"). Having identified segments of the genome 289 smaller than the whole, there are still at least six to ten segments to consider, each spanning many genes, a large 290 amount of information and a lot of variation. Depending upon the definition of peak region-whether 1Mb-5Mb 291 surrounding the focal SNP, or the larger regions bounded by a tenfold change in p-value-many genes that have been 292 associated with breast cancer risk in other studies are captured in the linkage regions (Table S1 ), including BRCA2. 293
From functional annotation, the linked regions we have identified encompass many genes that "look good" as 294 candidates for further analysis. However, in order to identify specific variants relevant to breast cancer phenotypes in 295 this study, especially those that are rare and of obscure overall effect, it remains to further interrogate the linkage 296 regions by sequencing. An efficient approach might begin with whole exome sequencing to address functional variants 297 first. Regional, functional, family and pair-specific information can all be used to direct targeted evaluations of 298 concordance between expected linkage (SNP-based probabilities of sharing IBD) generated by our model, anddifferences in sequence sharing per exome through the linked regions. By using the linkage-partitioned information 300 thus far, sequencing should reveal more specifically the locations of rarer variants likely relevant to the disease. 301
Linkage and sequencing techniques together should do much to clarify the genetic architecture of breast cancer in this 302 population, its heterogeneity among families [37] , and importantly, give us a deeper understanding of the role of rare 303 variants in conditioning risk differently among groups. 304
For any novel variants that might be established, or candidate genes that might be confirmed with sequencing, the 305 hope is that the information will advance knowledge of the genetic pathways involved and their interacting factors so 306 essential to personalized therapies, management, and outcomes in the clinical setting. The developing field of 307 Molecular Epidemiology and its unique integrative approach to medical research only begins with the address of large 308 and growing quantities of data for translation to improved risk prediction. Studies of this type, that inform us about 309 what specific genomic variation underlies risk variation in a population, lead to the identification of risk subgroups, 310 and most importantly, high-risk families and individuals. New and abundant genetic information will no doubt lead us 311 to understand important features of how genes-common, rare, and in multiplicity-contribute to disease spectra, 312 from well to mortal, and the intermediate. Table S1 . Table of shown. Crossing lines indicate inbreeding, although only one affected subject was herself inbred (family 18).
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Family numbers 2, 9, 15, 25 and 26 were assigned to families not used for this analysis, either because of overlap 439 with another family (2), or insufficient number of usable samples from breast cancer cases. The total number of distinct individuals. Some subjects were members of more than one family (see Table 1 ). 462 
